Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Milei Threatens Falkland Oil Firms With Sanctions 
Anthropic IPO Marketing Expected to Start in Mid-October 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Xiaomi Shares Jump on Europe EV Expansion Plan 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Add as a preferred source on Google
LEXINGTON, Mass., Feb. 20, 2018 -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that it will release its 2017 fourth quarter and full-year financial and operational results after the market closes on Tuesday, March 6, 2018. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Tuesday, March 6, 2018 to discuss the financial results and other business developments.
Interested parties may access the live call via telephone by dialing 1-877-407-9208 (U.S.) or 1-201-493-6784 (International). To listen to the live call via T2 Biosystems' website, go to www.t2biosystems.com, in the Investors/Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call, also in the Investors/Events & Presentations section of the website.
About T2 Biosystems:
T2 Biosystems is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today. The T2Sepsis Solution™ is a unique approach that combines the standard of care for the management of sepsis patients with T2 Biosystems’ products, including the T2Dx® Instrument and T2Candida® Panel, and the T2Bacteria® Panel, which is commercially available in Europe and other countries that accept the CE mark and available for research use only in the U.S. Powered by the proprietary T2 Magnetic Resonance technology, or T2MR®, the T2Sepsis Solution is proven to deliver better patient care and greater cost savings. Hospital customer experience has demonstrated faster time to effective treatment, shortened ICU and hospital lengths of stay, reduced use of unnecessary antifungals, and millions of dollars in savings. T2 Biosystems has an active pipeline of future sepsis products including additional species and antibiotic resistance, as well as tests for Lyme disease and hemostasis. For more information, please visit www.t2biosystems.com.
Media Contact:
Amy Phillips, Feinstein Kean Healthcare
[email protected]
412-327-9499
Investor Contact:
Chris Brinzey, Westwicke Partners
[email protected]
339-970-2843
